Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer M, Thomas CJ, Wei Y, Davani D, Guidos CJ, Khan J, Gladdy RA.
McKinnon T, et al.
Oncogene. 2018 May;37(20):2630-2644. doi: 10.1038/s41388-017-0122-y. Epub 2018 Feb 28.
Oncogene. 2018.
PMID: 29487419
Free PMC article.